Placebo-Controlled phase III Study of lenograstim (Glycosylated recombinant human granulocyte colony-Stimulating factor) in Aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration

References

• Devesa S. S., Fears T. Non Hodgkin's lymphma time trends: United States and International Data. Cancer Res. 1992; 52: 5432S–5440S, (Supp)
   PubMed Web of Science ®Google Scholar
• Longo D. L., De Vita V. T., Duffey P. L., Wesley M. N., Ihde D. C., Hubbard S. M., Gilliom M., Jaffe E. S., Cossman J., Fisher R. I., Young R. C. Superiority of Pro-MACE-Cytabom over ProMace-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J. Clin. Oncol. 1991; 9: 25–38
   PubMed Web of Science ®Google Scholar
• Shipp M. A., Harrington D. P., Klatt M. M., Jochelson M. S., Pinkus G. S., Marshall J. L., Rosenthal D. S., Skarin A. T., Canellos G. P. Identification of major prognostic subgroups of patient with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann. Intern. Med. 1986; 104: 757–765
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J. M. Updated clinical experience with MACOB-B. Semin. Hematol. 1987; 24: 26–34, suppl. 1
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E., Dahlberg S., Oken M. M., Grogran T. M., Mize E. M., Glick J. H., Coltman C. A., Jr., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Coiffier B., Gisselbrecht C., Herbrecht R., Tilly H., Bosly A., Brousse N. LNH84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J. Clin. Oncol. 1989; 7: 1018–1026
   PubMed Web of Science ®Google Scholar
• Coiffier B., Tilly H., Bosly A., Sebban C., Herbrecht R., Gisselbrecht C, GELA. Long-term follow-up of the 737 aggressive lymphoma patients treated in the LNH84 protocol: Very few relapses after 5 years. Blood 1993; 82: 1760, abstract
   Google Scholar
• Haioun C., Lepage E., Gisselbrecht C., Coiffier B., Bosly A., Tilly H., Morel P., Nouvel C., Herbrecht R., D'Agay M. F., Gaulard P., Reyes F., The Groupe d'Etude des Lymphomes de l'Adulte. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non Hodgkin's lymphoma in first complete remission: A study of 464 patients. J. Clin. Oncol. 1994; 12: 2543–2551
   PubMed Web of Science ®Google Scholar
• Lepage E., Gisselbrecht C., Haioun C., Sebban C., Tilly H., Bosly A., Morel P., Herbrecht R., Reyes F., Coiffier B, GELA. Prognostic significance of received relative dose intensity in non Hodgkin's lymphoma patients: Application to LNH87 protocol. Ann. Oncol. 1993; 4: 651–656
   PubMed Web of Science ®Google Scholar
• Pettengell R., Gurney H., Radford J. A., Deakin D. P., James R., Wilkinson P. M., Kane K., Bentley J., Crowther D. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 1992; 80: 1430–1436
   PubMed Web of Science ®Google Scholar
• Gerhartz H. H., Engelhard M., Meusers P., Brittinger G., Wilmanns W., Schlimok G., Mueller P., Huhn D., Musch R., Siegert W., Gerhartz D., Hartlapp J. H., Thiel E., Huber C., Peschl C., Spann W., Emmerich B., Schadek C., Westerhausen M., Pees H. W., Radtke H., Engert A., Terhardt E., Schick H., Binder T., Fuchs R., Hasford J., Brandmaier R., Stern A. C., Jones T. C., Ehrlich H. J., Stein H., Parwaresch M., Tiemann M., Lenner K. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non Hodgkin's lymphoma. Blood 1993; 82(8)2329–2339
   PubMed Web of Science ®Google Scholar
• Linch D. C., Scarffe H., Proctor S., Chopra R., Taylor P. R. A., Morgenstern G., Cunningham D., Burnett A. K., Cawley J. C., Franklin I. M., Bell A. J., Lister T. A., Marcus R. E., Newland A. C., Parker A. C., Yver A. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplantation 1993; 11: 307–311
   PubMed Web of Science ®Google Scholar
• Marty M. The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: A review. Ear. J. Cancer 1994; 30A: S20–S25
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C., Prentice H. G., Bacigalupo A., Biron P., Milpied N., Ruhie H., Cunningham D., Legros M., Pico J. L., Linch D. C., Burnett A. K., Scarffe J. H., Siegert W., Yver A. Placebo-controlled phase III trial lenograstim in bone marrow transplantation. Lancet 1994; 343: 696–700
   PubMed Web of Science ®Google Scholar
• Chevallier B., Chollet Ph., Merrouche Y., Roche H., Fumoleau P., Kerbrat P., Genot J. Y., Fargeot P., Oliver J. P., Fizames C., Clavel M., Yver A., Chabemaud Cour V. Lenograstim (rHuG-CSF) prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J. Clin. Oncol. 1995; 13: 1564–1571
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classiciations of non Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Musshoff K. Report of the committee on Hodgkin's disease staging. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• The International non Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observation. J. Am. Star. Assoc. 1958; 53: 547–581
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966; 50: 163–170
   PubMedGoogle Scholar
• Hryniuk W. M. The importance of dose intensity in the outcome of chemotherapy. Important advances in oncology, V. T. De Vita, S. Hellmann, S. A. Rosenberg. Lippincott, Philadelphia, P.A 1988; 121
   Google Scholar
• Nissen C., Dalle C. V., Moser Y. In vitro comparison of the biological potency of glycosylated versus nonglycosylated rG-CSF. Drug Invest. 1994; 7: 346–352
   Google Scholar
• Ota K., Ariyoshi Y., Fukuoka M. Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for lung cancer. Jpn. J. Cancer Chemother. 1990; 17: 65–71
   PubMedGoogle Scholar
• Lyman G. H., Lyman C. G., Sanderson R. A., Balducci L. Decision analysis of hematopoletic growth factor use in patients receiving cancer chemotherapy. J. Natl. Cancer Inst. 1993; 85: 1935–1936
   Google Scholar
• Broxmeyer H. E., Benninger L., Patel S. R., Benjamin R. S., Saroj Vadhan R. A.J. Kinetic responses of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp. Hematol. 1994; 22: 100–102
   PubMed Web of Science ®Google Scholar
• Souetre S., Qing W. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non Hodgkin's lymphoma. Pharmaco-Economics 1994; 6: 36–43
   Google Scholar
• Kauffman C. A., Liepman M. K., Bergman A. G., Mioduszewski J. Trimethoprim/Sulfamethoxazole prophylaxis in neutropenic patients. Amer. J. Med. 1983; 74: 599
   PubMed Web of Science ®Google Scholar
• Talcott J. A., Siegel R. D., Finberg R., Goldman L. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J. Clin. Oncol. 1992; 10: 316–322
   PubMed Web of Science ®Google Scholar
• Rubenstein E. B., Rolston K., Benjamin R. S., Loewy J., Escalante C., Manzullo E., Hughes P., Moreland B., Fender A., Kennedy K., Holmes F., Elting L., Bodey G. P. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71: 3640–3646
   PubMed Web of Science ®Google Scholar